Calcium-dependent enzyme that catalyzes the post-translational conversion of positively charged arginine residues to neutral citrulline in target proteins (citrullination). PAD4 is primarily expressed in neutrophils where it serves dual functions: facilitating antimicrobial NET formation during infection, and inadvertently creating autoantigenic neo-epitopes that trigger autoimmune responses in genetically susceptible individuals.
Imagine PAD4 as a molecular tailor that removes the "positive charge buttons" from protein garments (arginine residues) and replaces them with neutral "no-charge zippers" (citrulline residues). When neutrophils face infection, this tailor rushes to the chromatin wardrobe and begins frantically removing buttons from tightly packed histone proteins. Without their positive charges attracting the negatively charged DNA threads, the chromatin fabric springs open—like a coiled spring released—allowing the neutrophil to cast out a vast DNA net to trap bacteria (NETosis).
This is brilliant pathogen defense. But the tailor is indiscriminate. While modifying histones, PAD4 also wanders through the cellular workshop modifying other proteins—vimentin scaffolds, fibrinogen cables, collagen beams. These modified proteins now look "foreign" to the immune system, like furniture with all the buttons removed. In someone with the genetic predisposition (HLA-DR4 security system), immune sentries begin flagging these altered proteins as intruders. The body starts producing anti-citrullinated protein antibodies (ACPA)—essentially wanted posters for "proteins missing their buttons." This is how a defense mechanism (NET formation) becomes the architect of autoimmune disease (rheumatoid arthritis). The same tailor that saves you from pneumonia can, in the wrong genetic context with chronic activation (smoking, periodontal disease), trigger your immune system to attack your own modified proteins years before your joints start hurting.
PAD4 requires millimolar (mM) concentrations of Ca²⁺ for activation. Calcium binding induces conformational change → active site exposure → catalytic conversion:
Protein-Arginine + H₂O → Protein-Citrulline + NH₃
The positive charge on arginine's guanidinium group is lost, converting it to neutral ureido group of citrulline.
graph TD
A[Pathogen recognition] --> B["Ca²⁺ influx into neutrophil"]
B --> C[PAD4 activation]
C --> D[Histone citrullination H3/H4]
D --> E[Chromatin decondensation]
E --> F[Nuclear envelope breakdown]
F --> G[Mixing of nuclear/cytoplasmic components]
G --> H[Plasma membrane rupture]
H --> I["NET release: DNA + histones + MPO + elastase"]
I --> J[Pathogen trapping and killing]
C --> K[Off-target protein citrullination]
K --> L[Vimentin, fibrinogen, collagen modified]
L --> M{HLA-DR4 present?}
M -->|Yes| N[Neo-epitope presentation]
M -->|No| O[Tolerized/cleared]
N --> P[T cell activation]
P --> Q[B cell help]
Q --> R[ACPA production]
R --> S[Autoimmune cascade]
PAD4 citrullinates proteins with arginine-rich motifs:
- Histones H2A, H3, H4 → enables chromatin decondensation (NET formation)
- Vimentin → intermediate filament protein; major ACPA target in RA
- Fibrinogen → coagulation protein; citrullinated forms found in RA synovium
- Type II collagen → cartilage component; creates arthritogenic epitopes
- Keratin → structural protein; citrullinated in periodontal tissue
Citrullination → Loss of Positive Charge → Structural Alteration → Neo-epitope Formation
In HLA-DR4+ individuals:
- Antigen-presenting cells (macrophages, dendritic cells) phagocytose citrullinated proteins
- HLA-DR4 molecules have high affinity for citrullinated peptides (shared epitope: amino acid positions 70-74)
- HLA-DR4-citrullinated peptide complex presented to CD4+ T cells
- T cell activation → B cell help → ACPA production (IgG antibodies against citrullinated vimentin, fibrinogen, collagen)
- ACPA-immune complex formation → complement activation → joint inflammation
- Smoking: generates reactive oxygen species → increases PAD4 expression in lung tissue; directly modifies proteins making them better PAD4 substrates
- Periodontal disease: Porphyromonas gingivalis produces its own PAD enzyme (PPAD) → bacterial citrullination of host proteins
- Chronic inflammation: TNF-α and IL-1β upregulate PAD4 gene expression in neutrophils
- NETosis: releases massive amounts of citrullinated histones and other proteins into circulation
ACPA testing is 95-98% specific for rheumatoid arthritis. ACPA-positive RA has:
- Worse prognosis (more erosive disease)
- ACPA can appear 5-10 years before clinical symptoms
- Predictive value: ACPA+ individuals have 50% risk of developing RA within 5 years
PAD4 represents perfect example of selfish immune system trade-off:
- Benefit: Effective pathogen trapping via NETosis
- Cost: Autoantigen generation in genetically susceptible individuals with chronic activation
Evolutionary Mismatch Context:
- Hunter-gatherer: Intermittent infections → periodic PAD4 activation → NET formation → resolution → limited autoantigen exposure
- Modern: Chronic low-grade inflammation (smoking, periodontal disease, obesity, gut dysbiosis) → continuous PAD4 activity → persistent citrullinated protein exposure → breakdown of immune tolerance
Smoking increases RA risk 20-40-fold in HLA-DR4+ individuals through:
- Direct PAD4 upregulation in bronchial epithelium
- Chronic lung inflammation → neutrophil recruitment
- Generation of citrullinated proteins in lungs (primary site of ACPA development)
Periodontal disease (especially P. gingivalis colonization):
- Bacterial PAD directly citrullinates host proteins
- Creates oral citrullinated antigens
- Explains epidemiological link: 50% of RA patients have periodontal disease
Metamodel 5 Plus 2 Plus 1:
- Reduce chronic inflammatory triggers: smoking cessation, periodontal treatment, gut barrier restoration
- Minimize PAD4 substrate availability: reduce systemic inflammation (anti-inflammatory diet, omega-3s, specialized pro-resolving mediators)
- Support resolution pathways: enhance efferocytosis, promote resolvin production
- Monitor: ACPA testing in high-risk patients (HLA-DR4+, smokers, periodontal disease)
Pre-clinical RA window: Individuals with ACPA+ but no symptoms are ideal intervention targets—window to prevent disease development through lifestyle modification.
- ACPA >20 IU/mL: Considered positive (varies by assay)
- ACPA >100 IU/mL: High titer; strongly predictive of erosive RA
- Ca²⁺ requirement: PAD4 requires 2-5 mM Ca²⁺ for activation (physiological range 1-2 mM; achieved locally during cellular stress)
- PAD4 converts arginine → citrulline by removing positively charged NH₂ group, replacing with neutral oxygen
- Requires millimolar Ca²⁺ concentrations for enzymatic activity
- Expressed primarily in neutrophils, also in monocytes, macrophages, and mast cells
- Essential for NETosis: citrullinates histones H3 (Arg2, 8, 17) and H4 → chromatin decondensation
- ACPA (anti-citrullinated protein antibodies) are 95-98% specific for RA diagnosis
- ACPA can precede clinical RA symptoms by 5-10 years, providing intervention window
- Smoking increases RA risk 20-40-fold in HLA-DR4+ individuals via PAD4 upregulation in lungs
- HLA-DR4 "shared epitope" (positions 70-74) has high affinity for citrullinated peptides
- Porphyromonas gingivalis produces bacterial PAD enzyme (PPAD), linking periodontal disease to RA
- PAD4 inhibitors (e.g., Cl-amidine) are in development as potential RA therapeutics
- Citrullinated fibrinogen, vimentin, and type II collagen are primary autoantigens in RA
- NETs release contains citrullinated histones, myeloperoxidase, elastase, and cathepsins
- Citrullination — PAD4 is the primary enzyme catalyzing the citrullination reaction that converts arginine to citrulline in proteins
- Citrullinated proteins — PAD4 generates the pool of citrullinated self-proteins that become autoantigens in susceptible individuals
- ACPA — anti-citrullinated protein antibodies are produced against PAD4-modified proteins and define seropositive rheumatoid arthritis
- NETosis — PAD4-mediated histone citrullination is absolutely required for chromatin decondensation and NET release during neutrophil antimicrobial function
- neutrophils — primary cellular source of PAD4 expression; neutrophil activation drives both protective NETosis and pathogenic autoantigen generation
- rheumatoid arthritis — PAD4-generated citrullinated proteins (vimentin, fibrinogen, collagen) are the primary autoantigenic targets driving RA pathogenesis
- Calcium — PAD4 requires 2-5 mM Ca²⁺ for activation; calcium influx during cellular stress/activation gates PAD4 enzymatic activity
- HLA-B27 — while HLA-DR4 presents citrullinated peptides in RA, illustrates broader concept of HLA genetic risk for autoimmunity through altered antigen presentation
- smoking — dramatically enhances PAD4 expression in lung tissue and increases citrullinated protein generation, primary modifiable RA risk factor
- periodontal disease — oral bacterial PAD enzymes (especially from P. gingivalis) citrullinate host proteins, creating oral source of autoantigens
- Porphyromonas gingivalis — unique among human pathogens in producing its own PAD enzyme (PPAD), directly linking periodontal infection to RA autoantigen generation
- chronic inflammation — TNF-α and IL-1β upregulate PAD4 gene expression; chronic inflammatory states amplify citrullinated protein burden
- autoimmune disease — PAD4 exemplifies how normal immune defense mechanisms (NET formation) generate autoantigens when chronically activated in genetic susceptibility
- histones — PAD4 citrullinates histones H2A/H3/H4 at specific arginine residues, enabling chromatin decondensation essential for NET formation
- vimentin — intermediate filament protein; citrullinated vimentin is major ACPA target and found in high concentrations in RA synovial fluid
- fibrinogen — PAD4-citrullinated fibrinogen accumulates in RA joints and is immunogenic in HLA-DR4+ individuals
- collagen — type II collagen citrullination by PAD4 creates arthritogenic epitopes in cartilage, contributing to joint destruction in RA
- Molecular Mimicry — citrullinated self-proteins may structurally resemble microbial antigens, potentially explaining initial break in tolerance
- immune tolerance — chronic PAD4 activity and citrullinated protein accumulation can overwhelm tolerogenic mechanisms, especially in HLA-DR4+ individuals
- TNF-α — upregulates PAD4 expression in neutrophils; anti-TNF biologics may partly work by reducing PAD4-driven autoantigen generation
- IL-1β — induces PAD4 expression and neutrophil priming; IL-1 blockade reduces citrullination in inflammatory states
- CD4+ T cells — recognize HLA-DR4-presented citrullinated peptides, providing help for ACPA-producing B cells
- Reactive Oxygen Species — smoking-generated ROS increase PAD4 activity and make proteins better substrates for citrullination
- gut dysbiosis — emerging evidence links gut barrier dysfunction and bacterial translocation to systemic PAD4 activation and ACPA generation